Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients

Proteasome inhibitors (PIs) are highly active in multiple myeloma (MM) but resistance is commonly observed. All clinical stage PIs effectively inhibit chymotrypsin‐like (CT‐L) activity; one possible mechanism of resistance is compensatory hyperactivation of caspase‐like (C‐L) and trypsin‐like (T‐L)...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Haematol
Päätekijät: Levin, Nancy, Spencer, Andrew, Harrison, Simon J., Chauhan, Dharminder, Burrows, Francis J., Anderson, Kenneth C., Reich, Steven D., Richardson, Paul G., Trikha, Mohit
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2016
Aiheet:
Haematological Malignancy
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5084787/
https://ncbi.nlm.nih.gov/pubmed/27161872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14113
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia